

Gynevia

α-GOS PREBIOTIC & LACTIC ACID


THE SCIENTIFIC INNOVATION IN THE TREATMENT OF BACTERIAL VAGINOSIS SYMPTOMS

BACTERIAL VAGINOSIS, THE KEY FIGURES

- Bacterial vaginosis (BV) is one of the most common & serious type of vaginal infections with a prevalence of **20% in women of reproductive age**.
 - BV has a strong impact on quality of life due to bothersome symptoms (vaginal discomfort, malodorous & debilitating vaginal discharge) and can even lead to miscarriage during pregnancy.
 - The main risk factors are menstruations, antibiotics intake, sexual activity and pregnancy.
- **Metronidazole, the gold standard treatment for BV is associated with more than 50% relapses.**

BACTERIAL VAGINOSIS, AN UNBALANCED VAGINAL FLORA

Bacterial vaginosis is characterized by an unbalance of the healthy *Lactobacilli* in favor of the pathogen strain ***Gardnerella vaginalis*** associated with a pH modification.



WOMEN'S EXPECTATIONS

WOMEN SUFFERING FROM BV ARE WILLING TO RAPIDLY STOP THEIR UNPLEASANT SYMPTOMS AND DURABLY PREVENT THE OCCURENCE OF NEW VAGINAL INFECTIONS.

GYNEVIA, OUR SOLUTION FOR BACTERIAL VAGINOSIS



SPECIFIC & PATENTED α-GOS PREBIOTIC

3 years of collaboration with one of the leading European research centers have been required to develop **Gynevia's** complex prebiotic (α-GOS), which **promotes the selective growth of resident *Lactobacilli* (good flora)** to the detriment of pathogenic bacteria in the vagina.



CLINICALLY PROVEN

Gynevia treats bacterial vaginosis symptoms and **prevents relapses by durably restoring a normal pH and a balanced vaginal flora.** **Gynevia** eliminates malodorous vaginal discharge and relieves vaginal discomfort.



PHYSIOLOGICAL ACTION

Unlike hormones or antibiotics, **Gynevia** **physiologically restores a healthy and balanced vaginal flora** thanks to its **unique prebiotic's action.**





CONVENIENT FORM

The optimum viscosity of **Gynevia's** gel ensures a **consumer friendly application.**



GYNEVIA'S SELECTIVE AFFINITY WITH THE HEALTHY VAGINAL BACTERIA


Resulting from extensive biochemistry and molecular engineering researches, **Gynevia's** α -GOS presents a **complex and highly polymerized chain of oligosaccharides** selectively digested by healthy *Lactobacilli* but NOT by pathogen strains.



GYNEVIA, THE CLINICALLY PROVEN SOLUTION

The efficacy of **Gynevia** on bacterial vaginosis has been proven in 2 clinical studies including 78 women.

POST ANTIBIOTIC TREATMENT (n = 42)



- **100% of women treated with Gynevia have retrieved a healthy vaginal flora (Nugent Score ≤ 3) after 8 days of treatment while no evolution is measured in the lactic acid group.**
- **Bacterial vaginosis recurrence is reduced by 42% with the use of Gynevia after antibiotic therapy.**

PREVENTIVE TREATMENT (n = 36)

Inclusion criteria: women with a mean of 3 bacterial vaginosis per year

Percentage of new bacterial vaginosis cases within 6 months after Gynevia use



- **80.5% of women have not faced bacterial vaginosis relapses within the 6 months following the end of the treatment.**
- **Gynevia's preventive use durably restores vaginal balance, and thus stops bacterial vaginosis relapses.**

TECHNICAL INFORMATION

- **Actives:** Patented α -GOS prebiotic & Lactic acid
- **Quality:** Manufactured in EU following GMP and ISO 13485 standards
- **Recommended use:** 1 dose per day, for 8 consecutive days
- **Presentation:** Vaginal gel - 8 single doses
- **Regulatory:** Medical Device

GYNEVIA, THE SCIENTIFIC INNOVATION IN THE TREATMENT OF BACTERIAL VAGINOSIS SYMPTOMS

- **PATENTED & SPECIFIC α -GOS PREBIOTIC**
- **PREVENTS BACTERIAL VAGINOSIS RELAPSES**
- **CLINICALLY PROVEN**
- **RESTORES A NORMAL VAGINAL FLORA**



All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress provided herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.

